Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 2:10:782-790.
doi: 10.1016/j.dadm.2018.10.003. eCollection 2018.

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume

Affiliations

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume

Emrah Düzel et al. Alzheimers Dement (Amst). .

Abstract

Introduction: We examined the association between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, neural novelty responses, and brain volume in predementia old age.

Methods: We conducted a cross-sectional analysis of the observational, multicentric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study. Seventy-six participants completed task functional magnetic resonance imaging and provided CSF (40 cognitively unimpaired, 21 experiencing subjective cognitive decline, and 15 with mild cognitive impairment). We assessed the correlation between CSF biomarkers and whole-brain functional magnetic resonance imaging novelty responses to scene images.

Results: Total tau levels were specifically and negatively associated with novelty responses in the right amygdala and right hippocampus. Mediation analyses showed no evidence that these associations were dependent on the volume of hippocampus/amygdala. No relationship was found between phosphorylated-tau or Aβ42 levels and novelty responses.

Discussion: Our data show that CSF levels of total tau are associated with anatomically specific reductions in novelty processing, which cannot be fully explained by atrophy.

Keywords: Alzheimer's disease (AD); Apolipoprotein E (APOE); Aβ42; Cerebrospinal fluid (CSF); Longitudinal; Magnetic resonance imaging (MRI); Mild cognitive impairment (MCI); Positron emission tomography (PET); Subjective cognitive decline (SCD); Tau.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Correlation between CSF levels of total tau (pg/mL) and recognition memory accuracy (dprime) for the novel scenes presented during task-fMRI. Color codes indicate healthy controls (blue), subjective complainers (subjective cognitive decline, green), and individuals with mild cognitive impairment (mild cognitive impairment, orange).
Fig. 2
Fig. 2
Novelty activations and regression analyses. (A) Group-level contrast depicting increased BOLD responses to novel as compared to familiar scenes in the entire sample of 76 participants (depicted at P < .001 uncorrected, k = 400 voxels). Left panel shows entire activation map as a glass brain. Right panel depicts activation on group template (left is left). (B) Whole-brain regression analysis with CSF total tau levels. CSF total tau levels correlate selectively with novelty responses in the amygdala (left panel) and the hippocampus (right panel). Covariates were MRI sites (6 sites), age, gender, and Aβ42 levels. Abbreviations: CSF, cerebrospinal fluid; MRI, magnetic resonance imaging.
Fig. 3
Fig. 3
Mediation analyses. Total tau levels have a significant association with hippocampus + amygdala volume. The volume of hippocampus + amygdala, however, does not have a significant association with novelty. As expected (given the selection of the novelty cluster), there is also a significant influence on novelty responses in the hippocampus/amygdala clusters. More importantly, the direct effect of total tau levels on novelty responses remains significant after controlling for hippocampus/amygdala volume.

Similar articles

Cited by

References

    1. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 2002;298:789–791. - PubMed
    1. Holtzman D.M., Goate A., Kelly J., Sperling R. Mapping the road forward in Alzheimer's disease. Sci Transl Med. 2011;3:114ps48. - PubMed
    1. Motter n., Pelfrey V.C., Kholodenko D., Barbour R., Wood J.K., Galasko D. Reduction of amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643–648. - PubMed
    1. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–144. - PubMed
    1. Forlenza O.V., Radanovic M., Talib L.L., Aprahamian I., Diniz B.S., Zetterberg H. Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. Alzheimer's Demen (Amsterdam, Netherlands) 2015;1:455–463. - PMC - PubMed